Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 3/20 | 0.47 |
| ▸ | DRD3 | P35462 | 2/20 | 0.47 |
| ▸ | HTR2C | P28335 | 4/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 2/20 | 0.40 |
| ▸ | HTR2B | P41595 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.40 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.40 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.40 |
| ▸ | HTR7 | P34969 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12186541 | 1.00 | DRD2 (0.47) | DRD2DRD3HTR2CLMNAHTR2A | |
| SCHEMBL12186581 | 1.00 | DRD2 (0.47) | DRD2DRD3HTR2CLMNAHTR2A | |
| SCHEMBL15154597 | 1.00 | DRD2 (0.47) | DRD2DRD3HTR2CLMNAHTR2A | |
| SCHEMBL15154667 | 1.00 | DRD2 (0.47) | DRD2DRD3HTR2CLMNAHTR2A | |
| SCHEMBL20262047 | 1.00 | DRD2 (0.47) | DRD2DRD3HTR2CLMNAHTR2A | |
| SCHEMBL12186432 | 1.00 | DRD2 (0.47) | DRD2DRD3HTR2CLMNAHTR2A | |
| SCHEMBL15154720 | 1.00 | DRD2 (0.47) | DRD2DRD3HTR2CLMNAHTR2A | |
| SCHEMBL20262051 | 1.00 | DRD2 (0.47) | DRD2DRD3HTR2CLMNAHTR2A | |
| SCHEMBL7784267 | 0.83 | HTR2C (0.54) | DRD2HTR2CLMNAHTR2AHTR2B | |
| SCHEMBL936624 | 0.83 | HTR2C (0.54) | DRD2HTR2CLMNAHTR2AHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2571858-B1 | PHENYLMORPHOLINES AND ANALOGUES THEREOF | RES TRIANGLE INST (US) | 2018-06-20 | — | — | EP | claimed |
| US-9617229-B2 | Phenylmorpholines and analogues thereof | RESEARCH TRIANGLE INSTITUTE (US) | 2017-04-11 | — | — | US | claimed |
| US-20130203752-A1 | PHENYLMORPHOLINES AND ANALOGUES THEREOF | NIH-DEITR | 2013-08-08 | — | — | US | claimed |
| EP-2571858-A1 | PHENYLMORPHOLINES AND ANALOGUES THEREOF | Research Triangle Institute (US) | 2013-03-27 | — | — | EP | claimed |
| WO-2011146850-A1 | PHENYLMORPHOLINES AND ANALOGUES THEREOF | RESEARCH TRIANGLE INSTITUTE (US) | 2011-11-24 | — | — | WO | claimed |
| US-9617229-B2 | Phenylmorpholines and analogues thereof | RESEARCH TRIANGLE INSTITUTE (US) | 2017-04-11 | — | — | US | disclosed |
| US-20130203752-A1 | PHENYLMORPHOLINES AND ANALOGUES THEREOF | NIH-DEITR | 2013-08-08 | — | — | US | disclosed |
| EP-2571858-A1 | PHENYLMORPHOLINES AND ANALOGUES THEREOF | Research Triangle Institute (US) | 2013-03-27 | — | — | EP | disclosed |
| WO-2011146850-A1 | PHENYLMORPHOLINES AND ANALOGUES THEREOF | RESEARCH TRIANGLE INSTITUTE (US) | 2011-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130203752-A1 | PHENYLMORPHOLINES AND ANALOGUES THEREOF | PNMT, OPRL1, OPRM1 | DRD2 61/4885DRD3 117/4885HTR2C 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.